By means of in vitro and in vivo studies, it has been pointed out that lipid nanoparticles coated with hyaluronic acid (HA), a well-known ligand of CD44, and loaded with the taxane chemotherapy drug paclitaxel (PTX-loaded HA-SLNs) suppress the subpopulation of CD44+ melanoma cells [341]. Here, CD44 is linked to melanoma.